• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

出版信息

Lancet. 1992 Jan 11;339(8785):71-85.

PMID:1345869
Abstract
摘要

相似文献

1
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
Lancet. 1992 Jan 11;339(8785):71-85.
2
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.采用激素、细胞毒性或免疫疗法对早期乳腺癌进行全身治疗。133项随机试验，涉及75000名女性中的31000例复发和24000例死亡。早期乳腺癌试验协作组。
Lancet. 1992 Jan 4;339(8784):1-15.
3
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.早期乳腺癌的多药化疗：随机试验综述。早期乳腺癌试验者协作组
Lancet. 1998 Sep 19;352(9132):930-42.
4
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.他莫昔芬用于早期乳腺癌：随机试验综述。早期乳腺癌试验者协作组
Lancet. 1998 May 16;351(9114):1451-67.
5
Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.他莫昔芬与戈舍瑞林对比环磷酰胺、甲氨蝶呤和氟尿嘧啶的随机辅助治疗试验：绝经前激素反应性乳腺癌患者内分泌阻断治疗优越性的证据——奥地利乳腺癌和结直肠癌研究组试验5
J Clin Oncol. 2002 Dec 15;20(24):4621-7. doi: 10.1200/JCO.2002.09.112.
6
[Adjuvant therapy of breast cancer].[乳腺癌的辅助治疗]
Khirurgiia (Mosk). 2001(5):52-60.
7
[Sequencing of adjuvant treatment after surgery for invasive breast cancer].[浸润性乳腺癌术后辅助治疗的测序]
Cancer Radiother. 2004 Feb;8(1):54-8. doi: 10.1016/j.canrad.2003.10.006.
8
The EBCTCG overview of adjuvant therapy of breast cancer. What are the implications for future studies? Early Breast Cancer Trialists' Collaborative Group.早期乳腺癌试验者协作组：乳腺癌辅助治疗的EBCTCG综述。对未来研究有何启示？
Ann N Y Acad Sci. 1993 Nov 30;698:339-48. doi: 10.1111/j.1749-6632.1993.tb17224.x.
9
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.促黄体生成素释放激素激动剂在激素受体阳性绝经前乳腺癌患者中作为辅助治疗的应用：来自随机辅助试验的个体患者数据的荟萃分析
Lancet. 2007 May 19;369(9574):1711-23. doi: 10.1016/S0140-6736(07)60778-8.
10
[Adjuvant treatment of breast carcinoma].[乳腺癌的辅助治疗]
Ned Tijdschr Geneeskd. 1993 Nov 13;137(46):2364-70.

引用本文的文献

1
Menopause-related side effects in HR+ early breast cancer: insights from clinical practice.激素受体阳性早期乳腺癌中与绝经相关的副作用：来自临床实践的见解
Ther Adv Med Oncol. 2025 Jul 30;17:17588359251356105. doi: 10.1177/17588359251356105. eCollection 2025.
2
Estrogens and breast cancer.雌激素与乳腺癌
Ann Oncol. 2025 Feb;36(2):134-148. doi: 10.1016/j.annonc.2024.10.824. Epub 2024 Nov 8.
3
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare.
绝经前激素受体阳性、HER2阴性早期乳腺癌患者的全身治疗——医疗保健中的争议与标准
Geburtshilfe Frauenheilkd. 2023 May 23;83(6):673-685. doi: 10.1055/a-2073-1887. eCollection 2023 Jun.
4
Potential risk of tamoxifen: gut microbiota and inflammation in mice with breast cancer.他莫昔芬的潜在风险：乳腺癌小鼠的肠道微生物群与炎症
Front Oncol. 2023 Jul 4;13:1121471. doi: 10.3389/fonc.2023.1121471. eCollection 2023.
5
Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.三阴性乳腺癌中雌激素受体 β 的表达与复发或生存无关。
BMC Cancer. 2023 May 19;23(1):459. doi: 10.1186/s12885-023-10795-5.
6
Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data.乳腺癌：从癌症登记数据看转移、辅助和新辅助治疗的新原则。
J Cancer Res Clin Oncol. 2023 Feb;149(2):721-735. doi: 10.1007/s00432-022-04369-4. Epub 2022 Dec 20.
7
Systemic therapy for early-stage breast cancer: learning from the past to build the future.早期乳腺癌的系统性治疗：从过去中学习，为未来而建。
Nat Rev Clin Oncol. 2022 Dec;19(12):763-774. doi: 10.1038/s41571-022-00687-1. Epub 2022 Oct 17.
8
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.头颈部癌症化疗的荟萃分析（MACH-NC）：代表 MACH-NC 小组，对 107 项随机试验和 19805 名患者的最新更新。
Radiother Oncol. 2021 Mar;156:281-293. doi: 10.1016/j.radonc.2021.01.013. Epub 2021 Jan 27.
9
Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines.染色体不稳定性和克隆异质性在乳腺癌细胞系治疗反应中的作用。
Cancer Biol Med. 2020 Nov 15;17(4):970-985. doi: 10.20892/j.issn.2095-3941.2020.0028. Epub 2020 Dec 15.
10
Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer.早期乳腺癌辅助蒽环类和紫杉类方案的临床特征及预后趋势
World J Oncol. 2020 Jun;11(3):106-111. doi: 10.14740/wjon1284. Epub 2020 May 14.